MetaADEDB 2.0 @ LMMD
1-(3-chloro-5-((4-(4-chloro-2-thienyl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl)carbamoyl)-2-pyridyl)piperidine-4-carboxylic acid
(OFZJKCQENFPZBH-UHFFFAOYSA-N)
Structure
SMILES
OC(=O)C1CCN(CC1)c1ncc(cc1Cl)C(=O)Nc1sc(c(n1)c1scc(c1)Cl)N1CCN(CC1)C1CCCCC1
Type(s)
Approved; Investigational
ATC code(s)
B02BX08
Molecular Formula:
C29H34Cl2N6O3S2
Molecular Weight:
649.655
Log P:
6.7223
Hydrogen Bond Acceptor:
11
Hydrogen Bond Donor:
2
TPSA:
158.38
CAS Number(s):
570406-98-3
Synonym(s)
1.
1-(3-chloro-5-((4-(4-chloro-2-thienyl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl)carbamoyl)-2-pyridyl)piperidine-4-carboxylic acid
2.
AKR 501
3.
AKR-501
4.
AKR501
5.
E5501 compound
6.
YM 477
7.
YM-477
8.
YM477
9.
avatrombopag
External Link(s)
MeSHC533238
PubChem Compound9852519
CHEMBLCHEMBL2103883
DrugBankDB11995
IUPHAR/BPS Guide to PHARMACOLOGY9953
KEGGdr:D10306
ZINC72190218
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1HeadacheFAERS: 17US FAERS
2NauseaFAERS: 13US FAERS
3FatigueFAERS: 9US FAERS
4AstheniaFAERS: 5US FAERS
5Abdominal PainFAERS: 4US FAERS
6Inappropriate schedule of product administrationFAERS: 4US FAERS
7Product use complaintFAERS: 4US FAERS
8VomitingFAERS: 4US FAERS
9DizzinessFAERS: 3US FAERS
10Drug ineffectiveFAERS: 3US FAERS
11Portal Vein ThrombosisFAERS: 3US FAERS
12Abdominal discomfortFAERS: 2US FAERS
13DisorientationFAERS: 2US FAERS
14Feeling abnormalFAERS: 2US FAERS
15Hepatic EncephalopathyFAERS: 2US FAERS
16Myocardial InfarctionFAERS: 2US FAERS
17Peripheral swellingFAERS: 2US FAERS
18SomnolenceFAERS: 2US FAERS
19Accidental underdoseFAERS: 1US FAERS
20Acute myocardial infarctionFAERS: 1US FAERS
21Ammonia increasedFAERS: 1US FAERS
22Back PainFAERS: 1US FAERS
23Cold sweatFAERS: 1US FAERS
24ConstipationFAERS: 1US FAERS
25CystitisFAERS: 1US FAERS
26Depressed moodFAERS: 1US FAERS
27Drug effect incompleteFAERS: 1US FAERS
28EpistaxisFAERS: 1US FAERS
29Incorrect dose administeredFAERS: 1US FAERS
30Initial insomniaFAERS: 1US FAERS
31Joint swellingFAERS: 1US FAERS
32MalaiseFAERS: 1US FAERS
33Musculoskeletal discomfortFAERS: 1US FAERS
34No adverse eventFAERS: 1US FAERS
35PainFAERS: 1US FAERS
36Platelet aggregation abnormalFAERS: 1US FAERS
37Platelet count abnormalFAERS: 1US FAERS
38PneumoniaFAERS: 1US FAERS
39Product administration errorFAERS: 1US FAERS
40Product dose omissionFAERS: 1US FAERS
41Product label confusionFAERS: 1US FAERS
42Product packaging confusionFAERS: 1US FAERS
43Product prescribing errorFAERS: 1US FAERS
44Product prescribing issueFAERS: 1US FAERS
45Product use in unapproved indicationFAERS: 1US FAERS
46Product use issueFAERS: 1US FAERS
47PruritusFAERS: 1US FAERS
48Pulmonary EmbolismFAERS: 1US FAERS
49Sweating feverFAERS: 1US FAERS
50SwellingFAERS: 1US FAERS
51SyncopeFAERS: 1US FAERS
52ThrombosisFAERS: 1US FAERS
53White blood cell count decreasedFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120237

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.